8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

         Pursuant to Section 13 or 15(d) of the Securities Exchange Act

                                 March 24, 2004
                                ----------------
                                 Date of Report
                        (Date of Earliest Event Reported)

                        IMAGING DIAGNOSTIC SYSTEMS, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Florida                       0-26028                22-2671269

(State or Other Jurisdiction of (Commission File Number)   (I.R.S. Employer
 Incorporation or Organization)                          Identification Number)

                               6531 NW 18TH COURT
                              PLANTATION, FL 33313
               --------------------------------------------------
                    (Address of principal executive offices)


                                 (954) 581-9800
                    -----------------------------------------
                         (Registrant's telephone number)









Item 5.  OTHER EVENTS AND REGULATION FD DISCLOSUSRE

On March 24, 2004, at our Fiscal Year 2004 Annual Meeting of Stockholders, Dr.
Eric Milne, Chief Radiologist reported that a scientific paper from the
University of Vienna, (authors D. Floery, C. Riedl, W. Matzek, S. Jaromi, M.H.
Fuchsjaeger and T. Helbich, M.D.), describing the typical vascular appearances
of breast cancers imaged by our CTLM(R) Breast Imaging System at the University
of Vienna, Allgemeines Hospital was presented at the recent exhibition at the
European Congress of Radiology (ECR) held in Vienna. The paper has been
nominated for "Best and Original Paper for Breast Imaging" by the ECR.

Ms. Deborah O'Brien, Senior Vice-President announced that we would recognize
revenues of at least $540,000 for the third quarter ending March 31, 2004. She
also informed the shareholders that the FDA agreed with our request to have an
extension of time to respond to the FDA's August 22, 2003 letter regarding our
pre-market approval application.

We issued a press release, IMAGING DIAGNOSTIC SYSTEMS' ANNUAL SHAREHOLDER
MEETING HIGHLIGHTS PROGRESS, GROWTH AND REPORTABLE REVENUES, on March 25, 2004.
The press release, attached as Exhibit 99.1 hereto and incorporated herein by
reference is being furnished pursuant to Item 5.


SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                     IMAGING DIAGNOSTIC SYSTEMS, INC.

Dated March 25, 2004
                                     /s/ Linda B. Grable
                                     -------------------
                                     By: Linda B. Grable
                                     Chief Executive Officer and
                                     Chairman of the Board

                                     /s/ Allan L. Schwartz
                                     ---------------------
                                     By: Allan L. Schwartz
                                     Executive Vice President
                                     Chief Financial Officer

EX-99

IMAGING DIAGNOSTIC SYSTEMS' ANNUAL SHAREHOLDER MEETING
HIGHLIGHTS PROGRESS, GROWTH and REPORTABLE REVENUES

FOR IMMEDIATE RELEASE
Ft. Lauderdale, Fl., March 25, 2004--Imaging Diagnostic Systems Inc. (IDSI) (OTC
BB: IMDS) announced today that highlights of their annual shareholder meeting,
which was held yesterday at 9:00 am at their corporate headquarters, included
such announcements as reportable revenues from sales of the CT Laser Breast
Imaging System (CTLM(R)), technological advancements, and future business
strategies. The revenues of the sales will be reported in the Company's next
10-Q filing.

Dr. Eric Milne, Chief Radiologist, of IDSI reported that the company received
over 500 queries for the CTLM(R) at the recently attended European Congress of
Radiology (ECR), and was nominated for "Best and Original Paper for Breast
Imaging." Milne also mentioned that the studies underway using their CTLM(R)
system together with Schering's AG fluorescent dyes have been very encouraging."

In addition, Robert Wake, VP of Engineering of IDSI, made a presentation on the
potential market of the company's new Laser Imager for Laboratory Animals,
(LILA(TM)). Wake stated, "Optical Medical Imaging of laboratory animals to test
pharmaceuticals is an excellent market to enter because each specially bred
mouse can cost up to $30,000 and there are currently 30 million mice that are
used each year for this type of research."

According to Frost and Sullivan, a premier market and research firm, the animal
scanning market is a new frontier with a market value of $100 Million and a
projected annual growth in excess of 40%.

"If we can accelerate the typical 3 1/2 year testing cycle of a drug before it
can be tested on humans, we can save the pharmaceutical companies millions of
dollars. We anticipate that together with our partner, Rumbaugh-Goodwin
Institute for Cancer Research, we will be scanning mice before the end of this
year for this purpose," Wake added.

The meeting was brought to a close by Deborah O'Brien, Senior Vice President of
IDSI, who recited a summation of some of the Company's milestones this year,
which included, but were not limited to:

o    Canadian Market Approval
o    Sale of three CTLM(R)systems in China
o    Request of another CTLM(R)by Schering AG
o    Deposit received on a Purchase Order in Argentina
o    Nomination for Best and Original Paper on Breast Imaging at ECR
o    Collaborative Agreement with Rumbaugh-Goodwin Institute of Cancer Research


Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian
License, UL listing, ISO 9001:2000-13488 certification and FDA export
certification for its CT Laser Breast imaging system. The CTLM(R) system is the
first patented breast-imaging system that utilizes state-of-the-art laser
technology and patented algorithms to create 3-D cross-sectional images of the
breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug




Administration (FDA) for its CTLM(R) system to be used as an adjunct to
mammography. The CTLM(R) system is a non-invasive, painless examination that
does not expose the patient to radiation nor require breast compression.

Please visit Imaging Diagnostic Systems' website at: www.imds.com for additional
information.

In conjunction with the provisions of the Safe Harbor section of the Private
Securities Litigation Reform Act of 1995, this news release may contain
forward-looking statements pertaining to future anticipated projected plans,
performances and developments, as well as other statements relating to future
operations. All such forward-looking statements are necessarily only estimates
of future results and there can be no assurance that actual results will not
materially differ from expectation. Further information on potential factors
that could affect Imaging Diagnostic Systems, Inc., is included in the Company's
filing with the Securities Exchange Commission.

    Investor Relations:
    Rick Lutz
    Lcgroup@mindspring.com
    404-261-1196

    Media Relations:
    Margie Adelman
    madelman@adelmancommunications.com
    561-347-6768